Stock TLX TELIX PHARMACEUTICALS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Telix Pharmaceuticals Limited

Equities

TLX

AU000000TLX2

Biotechnology & Medical Research

Market Closed - Australian S.E.
Other stock markets
 11:40:11 03/05/2024 am IST 		5-day change 1st Jan Change
15.24 AUD +2.97% Intraday chart for Telix Pharmaceuticals Limited +2.21% +51.19%
03/05 Telix Pharmaceuticals Completes Acquisition of QSAM Biosciences and Drug Samarium-153-DOTMP MT
30/04 Bell Potter Downgrades Telix Pharmaceuticals to Hold from Buy, Price Target is AU$14.50 MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 392.6 1,060 2,209 2,300 3,263 5,036 - -
Enterprise Value (EV) 1 350.1 984.2 2,187 2,187 3,149 4,908 4,841 4,745
P/E ratio -13 x -21.7 x -27.2 x -21.7 x 626 x 101 x 48.4 x 39.5 x
Yield - - - - - - - -
Capitalization / Revenue 113 x 203 x 291 x 14.4 x 6.49 x 6.8 x 5.37 x 4.89 x
EV / Revenue 100 x 189 x 288 x 13.7 x 6.27 x 6.62 x 5.17 x 4.61 x
EV / EBITDA -14.3 x -28.5 x -31.2 x -32.3 x 53.9 x 49.1 x 29.5 x 27.3 x
EV / FCF - 575 x -35.2 x -29.9 x 223 x 76.7 x 38.3 x 42 x
FCF Yield - 0.17% -2.84% -3.35% 0.45% 1.3% 2.61% 2.38%
Price to Book 5.17 x 12.3 x 1,024 x 28.7 x 21.9 x 20.8 x 13.8 x 10.4 x
Nbr of stocks (in thousands) 2,53,280 2,80,405 2,85,073 3,16,343 3,23,727 3,30,450 - -
Reference price 2 1.550 3.780 7.750 7.270 10.08 15.24 15.24 15.24
Announcement Date 23/02/20 25/02/21 23/02/22 27/02/23 22/02/24 - - -
1AUD in Million2AUD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 3.485 5.213 7.596 160.1 502.5 740.9 937.2 1,030
EBITDA 1 -24.48 -34.59 -70.07 -67.8 58.44 99.9 163.9 174.1
EBIT 1 -28.71 -39.47 -75.25 -73.18 51.69 88.02 157.1 174.6
Operating Margin -823.93% -757.13% -990.61% -45.71% 10.29% 11.88% 16.76% 16.95%
Earnings before Tax (EBT) 1 -31.12 -47.94 -80.46 -98.62 3.087 77.84 145.7 182.3
Net income 1 -27.87 -44.89 -80.51 -104.1 5.211 48.56 103 126.9
Net margin -799.63% -861.06% -1,059.9% -65.01% 1.04% 6.55% 10.99% 12.31%
EPS 2 -0.1194 -0.1745 -0.2850 -0.3350 0.0161 0.1509 0.3146 0.3862
Free Cash Flow 1 - 1.712 -62.05 -73.17 14.15 64 126.5 113
FCF margin - 32.84% -816.93% -45.7% 2.82% 8.64% 13.5% 10.97%
FCF Conversion (EBITDA) - - - - 24.21% 64.06% 77.16% 64.91%
FCF Conversion (Net income) - - - - 271.52% 131.8% 122.86% 89.08%
Dividend per Share 2 - - - - - - - -
Announcement Date 23/02/20 25/02/21 23/02/22 27/02/23 22/02/24 - - -
1AUD in Million2AUD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2020 S1 2020 S2 2021 S1 2021 S2 2022 S1 2022 Q3 2022 Q4 2022 S2 2023 Q2 2023 S1 2023 S2 2024 Q2 2024 S1 2024 Q3 2024 Q4 2024 S2
Net sales 1 1.607 - 2.91 4.686 24.05 55.3 80.75 136 120.7 220.8 281.7 178 356.5 178 181 371
EBITDA - -23.56 -27.4 - - - - -7.046 - 34.72 23.71 - 52.7 - - 49.7
EBIT - - -29.94 -45.3 -63.48 - - -9.704 - 31.53 20.16 - -6.2 - - -6.2
Operating Margin - - -1,028.97% -966.79% -263.97% - - -7.13% - 14.28% 7.16% - -1.74% - - -1.67%
Earnings before Tax (EBT) - -28.69 -32.45 - -70.7 - - - - - - - - - - -
Net income - -26.59 -32.51 - -70.89 - - -33.19 - - 19.53 - 42.5 - - 38.4
Net margin - - -1,117.32% - -294.8% - - -24.39% - - 6.93% - 11.92% - - 10.35%
EPS -0.0722 -0.1023 -0.1156 - -0.2307 - - - - - - - - - - -
Dividend per Share - - - - - - - - - - - - - - - -
Announcement Date 20/08/20 25/02/21 18/08/21 23/02/22 17/08/22 19/10/22 27/02/23 27/02/23 23/08/23 23/08/23 22/02/24 - - - - -
1AUD in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 42.5 75.7 22 113 114 128 195 291
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 - 1.71 -62.1 -73.2 14.1 64 127 113
ROE (net income / shareholders' equity) -45.3% -60.2% -198% -253% 34.3% 22.9% 30.2% 26.7%
ROA (Net income/ Total Assets) - -34.5% -60.2% -57% 12% 26.2% 42.3% 32.7%
Assets 1 - 130.2 133.8 182.6 43.32 185.2 243.5 388.3
Book Value Per Share 2 0.3000 0.3100 0.0100 0.2500 0.4600 0.7300 1.100 1.460
Cash Flow per Share 2 -0.1000 0.0100 -0.2100 -0.2100 0.0700 0.2300 0.3200 0.4000
Capex 1 0.4 0.25 2.73 9.2 9.74 13.5 14.9 17
Capex / Sales 11.56% 4.76% 35.89% 5.75% 1.94% 1.83% 1.59% 1.65%
Announcement Date 23/02/20 25/02/21 23/02/22 27/02/23 22/02/24 - - -
1AUD in Million2AUD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Telix Pharmaceuticals Limited

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
15.24 AUD
Average target price
15.29 AUD
Spread / Average Target
+0.32%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
TELIX PHARMACEUTICALS LIMITED Stock Telix Pharmaceuticals Limited
+51.19% 3.33B
MODERNA, INC. Stock Moderna, Inc.
+25.69% 47.86B
LONZA GROUP AG Stock Lonza Group AG
+46.90% 41.42B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-3.46% 40.66B
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 28.92B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+9.17% 25.55B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-20.42% 19.27B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.17% 12.15B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+28.07% 12.14B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-1.24% 11.99B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. TLX Stock
  4. Financials Telix Pharmaceuticals Limited